21 03, 2018

CEO Money interviews Dr. Michael Lazar

2018-03-21T15:08:56+00:00 March 21st, 2018|

HIFU (High-Intensity Focused Ultrasound) is a minimally-invasive surgical procedure recently introduced to the U.S, and only available in a few markets. Yet, its continued use by surgeons is leading to increased interest in the device’s effectiveness – especially amid a national trend that sees more younger men being diagnosed with early-stage prostate cancer each year. A slower-acting cancer than others, many older men (65+) choose not to seek treatment to avoid the often-harmful after-effects of surgery or radiation. However, younger men (40+), have little choice but to accept treatment, or face early death. In development for several years, HIFU offers hope where traditional surgical methods have left men scarred physically and mentally. A robotics-based device using focused sound waves to heat and [...]

13 03, 2018

Random PSA screening misses some aggressive and lethal prostate cancers

2018-03-13T10:59:50+00:00 March 13th, 2018|

UK researchers say that inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives. This from the largest ever prostate cancer trial conducted over 10 years by Cancer Research UK-funded scientists and published in the Journal of the American Medical Association (JAMA). Researchers at the Universities of Bristol and Oxford found that testing asymptomatic men with PSA detects some disease that would be unlikely to cause any harm but also misses some aggressive and lethal prostate cancers. This highlights the flaws of a single PSA test as a way to screen for prostate cancer, and shows the need to find more accurate ways to diagnose cancers that need to be treated. The CAP Trial, which spanned almost [...]

6 03, 2018

New PET scan targets copper in tumors to detect prostate cancer

2018-03-06T07:35:43+00:00 March 6th, 2018|

An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level). Copper tends to be more concentrated in tumors, making it a good imaging biomarker. For this study of 50 patients, researchers conducted PET/CT scans comparing the new imaging agent, copper-64 chloride (64CuCl2), with fluorine-18-choline (18F-Choline). Multiparametric magnetic resonance imaging (mpMRI) was also conducted. In addition to calculating the detection rate of each imaging modality, the biodistribution, kinetics of the lesions and radiation dosimetry of 64CuCl2 were evaluated. "This is the first time this novel agent has been compared with 18F-Choline-PET/CT in a considerable number of prostate [...]

13 02, 2018

Blocking prostate cancer cells metabolism with drug therapy may inhibit growth

2018-02-13T09:06:03+00:00 February 13th, 2018|

For years, attempts have been made to understand the mechanism behind the proliferation of cancer cells: they need metabolites to grow and proliferate as much as a vehicle needs gasoline or electricity to move. However, until now it was not known which metabolites cancer cells actually need. A team of researchers from the Institute of Oncology Research (IOR) at the Università della Svizzera Italiana (USI, Faculty of Biomedical Sciences) led by Prof. Andrea Alimonti has identified one of the mechanisms behind this process, as published in a recent article in the journal Nature Genetics. From a theory dating back to the early 20th century by Nobel Prize laureate Otto Warburg, it has been believed that, in order to support their growth, cancer cells needed [...]

6 02, 2018

Cancerous tissue discernible from healthy tissue in prostate cancer patients

2018-02-06T08:27:54+00:00 February 6th, 2018|

Using nuclear medicine, researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research demonstrates that the maximum standardized uptake value (SUVmax) on 68Ga-PSMA PET/CT scans correlates with PSMA-expression in primary prostate cancer. By this means, researchers were able to generate an SUVmax cutoff for the differentiation of cancerous and benign prostate tissue. Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine. According to the American Cancer Society, one in nine men will be diagnosed with prostate cancer in his lifetime. Early diagnosis is key to successful treatment. The new [...]

1 02, 2018

How diabetes affects prostate cancer prognosis

2018-02-01T08:03:09+00:00 February 1st, 2018|

Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers were able to show that in the affected individuals the androgen receptor and the mitogenic forms of the insulin receptor were more strongly expressed. This could explain why patients with diabetes have a poorer prognosis for prostate cancer. Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers of the German Center for Diabetes Research (DZD) from Tübingen and experts of Helmholtz Zentrum München and the Urology Department of Tübingen University Hospital were able to show that in the affected individuals the androgen receptor and the mitogenic forms [...]

23 01, 2018

New study shows that some cases of aggressive prostate cancer may be linked to high-fat diet

2018-01-23T09:50:13+00:00 January 23rd, 2018|

Dr. Michael Lazar of California HIFU shares insights from a new study on prostate cancer, emphasizing that a healthy diet may contribute to prevention of the disease. There have been many discoveries recently that identify a link between a diet rich in fatty foods and increased risk of prostate cancer. The evidence continues to mount with the results of this new study investigating the effects of high-fat diets on certain prostate cancer tumors. Researchers at the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) discovered genetic mechanisms that promote cancer tumor metastasis, pointing to the typical Western high-fat diet as a key factor in driving that metastasis. The study was published this week in two journals; Nature Genetic and Nature Communications. It compared [...]

16 01, 2018

New genetic tool predicts age for onset of aggressive prostate cancer

2018-01-16T14:30:43+00:00 January 16th, 2018|

Researchers developed genetic tool for predicting onset of aggressive prostate cancer An international team, led by researchers at the University of California San Diego School of Medicine, has developed and validated a genetic tool for predicting age of onset of aggressive prostate cancer, a disease that kills more than 26,000 American men annually. The tool, described in the January 11 online issue of the BMJ(formerly the British Medical Journal), may potentially be used to help guide decisions about who to screen for prostate cancer and at what age. Currently, detection of prostate cancer relies primarily upon the prostate-specific antigen (PSA) screening blood test. But PSA testing is not very good as a screening tool. While it reduces deaths from prostate cancer, indiscriminate PSA screening also [...]

9 01, 2018

New roadmap developed to genetically test for hereditary prostate cancer

2018-01-09T08:50:54+00:00 January 9th, 2018|

A roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer has been developed by a team of researchers. To date, there have been few recommendations to guide physicians about when to offer men genetic consultation for prostate cancer risk. Now, an international and inter-specialty panel of experts convened at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University have developed a comprehensive set of recommendations. This consensus statement, published December 13th in the Journal of Clinical Oncology, will help physicians and stakeholders make sense of a rapidly evolving field of practice. "There is increasing recognition that some prostate cancers can be inherited. Genetic testing could provide men and their families with information about cancer [...]

2 01, 2018

#1 New Year’s Resolution for Men: Get screened for prostate cancer

2018-01-02T13:01:35+00:00 January 2nd, 2018|

#1 New Year’s Resolution for Men: Get screened for prostate cancer   Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options; says early detection saves lives. “Knowing the many options for treating prostate cancer is something all men at risk of developing the disease need to be informed about,” says Dr. Lazar. “Most men know about the unpleasant side effects that go along with traditional models of prostate cancer treatment, including urinary incontinence, bowel and erectile dysfunction. But some of the newer treatment modalities such as HIFU (high-intensity focused ultrasound) can only be undertaken at the early stages, when damage to surrounding tissue can best be mitigated, and most side effects eliminated.” Why Early [...]